Liver Cancer
Copyright ©The Author(s) 2004. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 15, 2004; 10(14): 2034-2038
Published online Jul 15, 2004. doi: 10.3748/wjg.v10.i14.2034
Expression of cancer-testis antigens in hepatocellular carcinoma
Li Zhao, Dong-Cheng Mou, Xi-Sheng Leng, Ji-Run Peng, Wan-Xiang Wang, Lei Huang, Shu Li, Ji-Ye Zhu
Li Zhao, Xi-Sheng Leng, Ji-Run Peng, Wan-Xiang Wang, Lei Huang, Shu Li, Ji-Ye Zhu, Center of Hepatobiliary Surgery, People’s Hospital, Peking University, Beijing 100044, China
Dong-Cheng Mou, Department of General Surgery, First Affiliated Hospital of TsingHua University, Beijing 100016, China
Author contributions: All authors contributed equally to the work.
Supported by the National Natural Science Foundation of China, No. 30200271, and the National Key Technologies Research and Development Program of China during the 9th Five-Year Plan Period, No. 2001BA703B04, and the Clinical Program of Ministry of Health of China (2001) and Center for Human Disease Genomics of Peking University (2001-6)
Correspondence to: Dr. Xi-Sheng Leng, Center of Hepatobiliary Surgery, People’s Hospital, Peking University, 11 XiZhimen Nandajie, West District, Beijing 100044, China. lengxs2003@yahoo.com.cn
Telephone: +86-10-68314422-3500
Received: February 2, 2004
Revised: February 15, 2004
Accepted: February 21, 2004
Published online: July 15, 2004
Abstract

AIM: To investigate the expression of cancer-testis (CT) antigens MAGE-1, SSX-1 ,CTp11 and HCA587 genes in hepatocellular carcinoma (HCC) and the possibility of applying these antigens as targets for specific immunotherapy for HCC.

METHODS: Expression levels of MAGE-1, SSX-1, CTp11 and HCA587 mRNA were detected with reverse transcription polymerase chain reaction (RT-PCR) in HCC tissues and corresponding adjacent non-cancerous tissues from 105 HCC patients, 40 samples of cirrhosis and normal liver tissues. Genes of five samples with positive PCR results were sequenced.

RESULTS: Of 105 HCC tissues, MAGE1, SSX-1 ,CTp11 and HCA587 mRNA expressions were detectable in 75.2% (79/105), 72.4% (76/105), 62.9% (66/105) and 56.2% (59/105) of HCC samples, respectively. About 93.3% (98/105), 72.4% (76/105), 48.6% (51/105) and 37.1% (39/105) of HCC tissues positively expressed at least one, two, three, and four members of CT antigens, respectively. Conversely, only SSX-1 could be detectable in 2.9% (3/105) of the corresponding adjacent non-HCC tissues in which no metastatic lesion was found. Of the latter 3 patients, biopsy samples far from tumor were obtained in 2 patients and RT-PCR indicated no expression of SSX-1 mRNA in these two samples. In addition, none of 40 samples of cirrhotic and normal liver tissues expressed CT antigen gene mRNA. DNA sequences confirmed that the RT-PCR products were true target cDNA. No relationship was found between expression of CT antigens and clinico pathological indicators such as age, gender, tumor size, degree of tumor differentiation, serum α-fetoprotein level and infection of hepatitis B virus or hepatitis C virus (P > 0.05).

CONCLUSION: CT antigens genes (MAGE-1, SSX-1, CTp11 and HCA587) are expressed with high percentage and specificity in HCC and their products are promising targets for antigen-specific immunotherapy of HCC. High frequent co-expression of multiple members of CT antigens in HCC provides possibility of polyvalent vaccinations for HCC.

Keywords: $[Keywords]